---
document_datetime: 2025-11-23 08:05:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-teva-pharma-bv.html
document_name: clopidogrel-teva-pharma-bv.html
version: success
processing_time: 0.1069419
conversion_datetime: 2025-12-25 10:55:30.356889
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Clopidogrel Teva Pharma B.V.

[RSS](/en/individual-human-medicine.xml/66077)

##### Withdrawn

This medicine's authorisation has been withdrawn

clopidogrel

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 October 2014 the European Commission withdrew the marketing authorisation for Clopidogrel Teva Pharma B.V. (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva Pharma B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Clopidogrel Teva Pharma B.V. was granted marketing authorisation in the EU on 16 June 2011 for the prevention of atherothrombotic events (problems caused by blood clots and hardening of the arteries). The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU.

Clopidogrel Teva Pharma B.V. is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Clopidogrel Teva Pharma B.V. is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Clopidogrel Teva Pharma B.V. : EPAR - Summary for the public

English (EN) (540.03 KB - PDF)

**First published:** 30/06/2011

**Last updated:** 03/02/2015

[View](/en/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-442)

български (BG) (705.18 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/bg/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_bg.pdf)

español (ES) (604.09 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/es/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_es.pdf)

čeština (CS) (672.12 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/cs/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_cs.pdf)

dansk (DA) (606.07 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/da/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_da.pdf)

Deutsch (DE) (605.89 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/de/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_de.pdf)

eesti keel (ET) (604.13 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/et/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_et.pdf)

ελληνικά (EL) (712.8 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/el/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_el.pdf)

français (FR) (605.69 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/fr/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_fr.pdf)

italiano (IT) (605.94 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/it/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_it.pdf)

latviešu valoda (LV) (675.43 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/lv/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (632.93 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/lt/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_lt.pdf)

magyar (HU) (665.91 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/hu/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_hu.pdf)

Malti (MT) (670.97 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/mt/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_mt.pdf)

Nederlands (NL) (605.92 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/nl/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_nl.pdf)

polski (PL) (673.63 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/pl/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_pl.pdf)

português (PT) (605.15 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/pt/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_pt.pdf)

română (RO) (632.19 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/ro/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_ro.pdf)

slovenčina (SK) (668.84 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sk/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_sk.pdf)

slovenščina (SL) (603.79 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sl/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_sl.pdf)

Suomi (FI) (604.72 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/fi/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_fi.pdf)

svenska (SV) (603.27 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sv/documents/overview/clopidogrel-teva-pharma-bv-epar-summary-public_sv.pdf)

## Product information

Clopidogrel Teva Pharma B.V. : EPAR - Product Information

English (EN) (770.74 KB - PDF)

**First published:** 30/06/2011

**Last updated:** 03/02/2015

[View](/en/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-258)

български (BG) (1.39 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/bg/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_bg.pdf)

español (ES) (880.1 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/es/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_es.pdf)

čeština (CS) (1.38 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/cs/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_cs.pdf)

dansk (DA) (859.63 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/da/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_da.pdf)

Deutsch (DE) (866.92 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/de/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_de.pdf)

eesti keel (ET) (821.94 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/et/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_et.pdf)

ελληνικά (EL) (1.89 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/el/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_el.pdf)

français (FR) (851.75 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/fr/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_fr.pdf)

hrvatski (HR) (920.07 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/hr/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_hr.pdf)

íslenska (IS) (864.13 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/is/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_is.pdf)

italiano (IT) (879.13 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/it/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_it.pdf)

latviešu valoda (LV) (1.47 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/lv/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_lv.pdf)

lietuvių kalba (LT) (976.81 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/lt/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_lt.pdf)

magyar (HU) (1.36 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/hu/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_hu.pdf)

Malti (MT) (1.41 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/mt/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_mt.pdf)

Nederlands (NL) (840.91 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/nl/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_nl.pdf)

norsk (NO) (851.04 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/no/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_no.pdf)

polski (PL) (1.5 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/pl/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_pl.pdf)

português (PT) (878.4 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/pt/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_pt.pdf)

română (RO) (964.23 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/ro/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_ro.pdf)

slovenčina (SK) (1.48 MB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sk/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_sk.pdf)

slovenščina (SL) (256.76 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sl/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_sl.pdf)

Suomi (FI) (827.65 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/fi/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_fi.pdf)

svenska (SV) (843.03 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sv/documents/product-information/clopidogrel-teva-pharma-bv-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0009/G 21/10/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Clopidogrel Teva Pharma B.V. : EPAR - All Authorised presentations

English (EN) (501.33 KB - PDF)

**First published:** 30/06/2011

**Last updated:** 03/02/2015

[View](/en/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-989)

български (BG) (554.8 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/bg/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_bg.pdf)

español (ES) (513.44 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/es/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_es.pdf)

čeština (CS) (516.64 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/cs/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (502.23 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/da/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (499.79 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/de/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (513.14 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/et/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (566.66 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/el/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_el.pdf)

français (FR) (508.13 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/fr/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (501.91 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/is/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_is.pdf)

italiano (IT) (501.09 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/it/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (537.49 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/lv/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (532.1 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/lt/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (543.64 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/hu/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (555.5 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/mt/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (493.68 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/nl/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (502.13 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/no/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_no.pdf)

polski (PL) (555.5 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/pl/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_pl.pdf)

português (PT) (513.12 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/pt/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_pt.pdf)

română (RO) (542.44 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/ro/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (553.39 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sk/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (530.84 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sl/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (501.85 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/fi/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (493.65 KB - PDF)

**First published:**

30/06/2011

**Last updated:**

03/02/2015

[View](/sv/documents/all-authorised-presentations/clopidogrel-teva-pharma-bv-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Clopidogrel Teva Pharma B.V. Active substance clopidogrel (as hydrobromide) International non-proprietary name (INN) or common name clopidogrel Therapeutic area (MeSH)

- Peripheral Vascular Diseases
- Acute Coronary Syndrome
- Myocardial Infarction
- Stroke

Anatomical therapeutic chemical (ATC) code B01AC04

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Prevention of atherothrombotic events

Clopidogrel is indicated in:

- adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;
- adult patients suffering from acute coronary syndrome:
    - non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
    - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

## Authorisation details

EMA product number EMEA/H/C/001226

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Teva Pharma B.V.

Marketing authorisation issued 16/06/2011 Withdrawal of marketing authorisation 21/10/2014 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Clopidogrel Teva Pharma B.V. : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (591.09 KB - PDF)

**First published:** 16/08/2012

**Last updated:** 03/02/2015

[View](/en/documents/procedural-steps-after/clopidogrel-teva-pharma-bv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Clopidogrel Teva Pharma B.V. : EPAR - Public assessment report

Adopted

Reference Number: WC500108104.pdf

English (EN) (989.96 KB - PDF)

**First published:** 30/06/2011

**Last updated:** 03/02/2015

[View](/en/documents/assessment-report/clopidogrel-teva-pharma-bv-epar-public-assessment-report_en.pdf)

CHMP positive summary of opinion for Clopidogrel Teva Pharma B.V.

Adopted

Reference Number: EMA/CHMP/289096/2010

English (EN) (517.32 KB - PDF)

**First published:** 23/07/2010

**Last updated:** 03/02/2015

[View](/en/documents/smop-initial/chmp-positive-summary-opinion-clopidogrel-teva-pharma-bv_en.pdf)

**This page was last updated on** 03/02/2015

## Share this page

[Back to top](#main-content)